UroGen acquires ICVB-1042 assets from IconOVir for shares, milestone, and royalties

UroGen Pharma Ltd.

UroGen issued 374,843 ordinary shares (worth $4.0M) to IconOVir as upfront consideration.
UroGen agreed to pay $15.0M cash milestone on cumulative global net sales of ICVB-1042 products.
UroGen will pay low single-digit royalties on worldwide net sales of ICVB Products.
Entities affiliated with Chair Arie Belldegrun hold promissory notes entitling them to ~28.3% of purchase price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.